EverImmune (FR)

https://www.everimmune.com

LinkedIn: https://www.linkedin.com/company/everimmune

EverImmune is a biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology. It harnesses the gut microbiota for the development of a unique theragnostic approach aiming to restore the response of Immune Checkpoint Inhibitors (ICIs) in cancer patients. The company is developing Oncobax® AK, a Live Biotherapeutic Product (LBP) used as an oral adjuvant to anticancer immunotherapies, designed to safely boost the immune system and restore sensitivity to immunotherapies in primary resistance settings. EverImmune started its phase I clinical trial for Oncobax AK in Q3 2022, in Non-Small Cell Lung Cancer (NSCLC) and Renal Cell Cancer (RCC) patients. It also develops other bacteria in its pipeline for use in the treatment of different types of cancer, such as breast and colon cancers. Created in 2016 by co-founders Pr. Laurence Zitvogel and Dr. Romain Daillere, everImmune is a spinoff from Gustave Roussy; Europe’s first cancer institute, based near Paris, France. The company is part of ONCOBIOME, the first European program dedicated to microbiome and cancer, funded by the European Union. Based in Villejuif, near Paris, everImmune has seven staff. *

	Start	2016-01-01 established (s-off)
	Predecessor	Institut Gustave Roussy (IGR)
	Industry	microbiomic treatment (live biotherapeutic product, LBP)
	Industry 2	cancer immunotherapy (immuno-oncology, I-O)

	Region	Villejuif
	Country	France
	Street	39 Rue Camille Desmoulins
	City	94800 Villejuif
		Address record changed: 2021-12-01

Basic data	Employees	A: 1 to 10 (2023-09-15)

		* Document for »About Section«: EverImmune. (9/19/23). "Press Release: EverImmune Secures €3.5 Million in Financing from Bpifrance". Villejuif.

		Record changed: 2024-02-12

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for EverImmune (FR)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)